DSP-2230 is a selective, small-molecule Nav1.7 and Nav1.8 voltage-gated sodium channel blocker under development by Dainippon Sumitomo Pharma for the treatment of neuropathic pain.[1][2] As of June 2014, it is in phase I/phase II clinical trials.[1][2]

See also


  1. 1 2 Martz, Lauren (2014). "Nav-i-gating antibodies for pain". Science-Business eXchange. 7 (23). doi:10.1038/scibx.2014.662. ISSN 1945-3477.
  2. 1 2 Bagal, Sharan K.; Chapman, Mark L.; Marron, Brian E.; Prime, Rebecca; Ian Storer, R.; Swain, Nigel A. (2014). "Recent progress in sodium channel modulators for pain". Bioorganic & Medicinal Chemistry Letters. 24 (16): 3690–9. doi:10.1016/j.bmcl.2014.06.038. ISSN 0960-894X. PMID 25060923.

This article is issued from Wikipedia - version of the 3/26/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.